CRBU · Caribou Biosciences, Inc.
$0.47
-0.01 (-2.33%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$52.54M
Shares
107.21M
Volume · Oct 8
19.34M
Avg daily vol (3M)
2.15M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.48
Open$0.59
Day$0.45–0.60
52W close$0.48–2.84
Avg vol 30d3.1M
Short int13.0M · 12.1% float · 9.5d
Short vol70%
Last earningsMay 7, 2026
DataJul 2021–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Oct 4, 2027
Est · unconfirmed
· in 51 wks
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$10.04M
Trailing 12 months
Net income (TTM)
−$103.40M
Trailing 12 months
Revenue growth YoY
-43.8%
Year over year
Operating margin
-1,090.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.6%
Year over year · more shares
Price change (1Y)
-51.5%
Trailing year
Short interest
12.1%
Latest settlement · 9.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−72%
below
Price vs 50-day avg
−66%
below
RSI (14)
11
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−65%
trailing
6-month return
−78%
trailing
YTD return
−70%
this year
Relative strength
−87%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
4 of 137 funds reported for Sep 30 · net +195.4K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.11% of float · ▲ +3.8% MoM · 9.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
137 holders — mid 3-yr range
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+12%
Y/Y
EPS growth
+4%
Y/Y
Free cash flow
$-112.4M
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−83%
past year
ATR
22.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 13, 2023
Cash, cash equivalents, and marketable securities
· as of June 30, 2023
$292.5M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−72%
Bearish
Price vs 50-day avg
−66%
Bearish
RSI (14)
11
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
4 of 137 funds reported for Sep 30 · net +195.4K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.11% of float · ▲ +3.8% MoM · 9.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
137 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $3
vs 200-day avg -72%
vs 50-day avg -66%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRBU
this stock
Caribou Biosciences, Inc.
|
$52.54M | -69.7% | +11.7% | — | 12.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.55B | +11.0% | +46.2% | 29.3 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.3 | 2.5% |
|
CSLLY
Csl Ltd
|
$60.24B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRBU | -60.6% | -64.9% | -78.1% | -62.1% | -69.7% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -61.9% | -67.0% | -87.1% | -63.6% | -83.2% |